HomeCompareIDRSF vs EPRT

IDRSF vs EPRT: Dividend Comparison 2026

IDRSF yields 48.90% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IDRSF wins by $307.9K in total portfolio value
10 years
IDRSF
IDRSF
● Live price
48.90%
Share price
$4.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$372.2K
Annual income
$74,100.38
Full IDRSF calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — IDRSF vs EPRT

📍 IDRSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIDRSFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IDRSF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IDRSF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IDRSF
Annual income on $10K today (after 15% tax)
$4,156.48/yr
After 10yr DRIP, annual income (after tax)
$62,985.32/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, IDRSF beats the other by $51,790.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IDRSF + EPRT for your $10,000?

IDRSF: 50%EPRT: 50%
100% EPRT50/50100% IDRSF
Portfolio after 10yr
$218.3K
Annual income
$43,635.62/yr
Blended yield
19.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

IDRSF
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-10.1
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IDRSF buys
0
EPRT buys
0
No recent congressional trades found for IDRSF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIDRSFEPRT
Forward yield48.90%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$372.2K$64.3K
Annual income after 10y$74,100.38$13,170.85
Total dividends collected$295.4K$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: IDRSF vs EPRT ($10,000, DRIP)

YearIDRSF PortfolioIDRSF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$15,590$4,889.98$11,212$512.01+$4.4KIDRSF
2$23,806$7,124.73$12,689$692.09+$11.1KIDRSF
3$35,640$10,167.77$14,521$944.30+$21.1KIDRSF
4$52,361$14,226.41$16,841$1,302.88+$35.5KIDRSF
5$75,560$19,533.63$19,841$1,821.64+$55.7KIDRSF
6$107,194$26,344.00$23,818$2,587.47+$83.4KIDRSF
7$149,625$34,927.92$29,230$3,744.65+$120.4KIDRSF
8$205,663$45,564.28$36,816$5,540.38+$168.8KIDRSF
9$278,591$58,531.92$47,806$8,413.17+$230.8KIDRSF
10$372,193$74,100.38$64,324$13,170.85+$307.9KIDRSF

IDRSF vs EPRT: Complete Analysis 2026

IDRSFStock

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Full IDRSF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this IDRSF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IDRSF vs SCHDIDRSF vs JEPIIDRSF vs OIDRSF vs KOIDRSF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.